Companies
/
Benchling

Enterprise Software
Benchling is a San Francisco-based software company providing a cloud-based platform for biotech and life sciences companies to manage laboratory research data and workflows.
$1.1B
+$5.30
896.81%
30 days ago
$0.59
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Sign up with Augment to see the latest market activity.
Benchling was founded in 2012 by Sajith Wickramasekara and Ashu Singhal, Stanford classmates who identified that biology researchers, in academic labs and, increasingly, well-funded biotech companies, were managing enormously complex, high-value experimental data using tools poorly suited to the task, such as paper lab notebooks, spreadsheets, and disconnected point software, making it difficult to track experiments, collaborate across a growing research team, and maintain compliant records for eventual regulatory submissions. Benchling's cloud-based platform provides an electronic lab notebook that lets researchers record and organize experimental protocols and results, molecular biology tools for designing and tracking DNA and protein sequences, and broader laboratory information management system (LIMS) capabilities for tracking physical samples, inventory, and workflows across a lab or company. The company's platform has become particularly important infrastructure for the growing number of well-funded biotech companies working in areas like gene editing, synthetic biology, and cell and gene therapy, where research processes are especially data-intensive and where maintaining rigorous, auditable records is important both for scientific reproducibility and for eventual regulatory submissions to agencies like the FDA. Benchling has positioned its platform as purpose-built specifically for life sciences research and development workflows, differentiating from more generic laboratory software or repurposed general-purpose data tools, and has expanded its offerings to cover broader R&D data management, biologics discovery workflows, and increasingly AI-assisted research tools tailored to biological data types. The company counts many prominent biotech and pharmaceutical companies among its customers. Benchling has raised very substantial venture funding from investors including Benchmark, Thrive Capital, and Altimeter Capital, reaching a valuation of several billion dollars as biotech R&D has become an increasingly software- and data-intensive discipline.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.